Argonaut Manufacturing Services and the nonprofit n-Lorem Foundation said they have entered into a partnership that supports and reduces the cost of manufacturing of n-Lorem’s experimental antisense oligonucleotide (ASO) medicines developed for rare disease patient populations of 30 or less and that are free for life.
“Providing nano-rare patients, who would otherwise be largely ignored by our current drug discovery paradigm, with a personalized approach for free is a remarkable undertaking and one that requires the commitment of many people and organizations,” said Stanley Crooke, founder, CEO, and Chairman of n-Lorem Foundation. “Reducing the cost of manufacturing translates into lower per-patient costs, which is important for our nonprofit and important for our patients who depend upon us and our partners.”
Argonaut will provide the sterile fill finish, the final step of producing these life-saving therapies. The company said its platform and expertise in drug product manufacturing were designed specifically for small batch drug product manufacturing that is specifically valuable for rare and orphan disease.
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.